The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2018

Filed:

Nov. 17, 2016
Applicant:

Glaxosmithkline Biologicals S.a., Rixensart, BE;

Inventor:

Pierre Vandepapeliere, Rixensart, BE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/39 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61K 39/015 (2006.01); A61K 39/09 (2006.01); A61K 39/102 (2006.01); A61K 39/104 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/00 (2013.01); A61K 39/015 (2013.01); A61K 39/092 (2013.01); A61K 39/102 (2013.01); A61K 39/1045 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/57 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16171 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/16771 (2013.01); C12N 2710/20071 (2013.01); C12N 2730/10134 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16271 (2013.01); C12N 2760/20034 (2013.01); Y02A 50/412 (2018.01);
Abstract

The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark ofpresented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome.


Find Patent Forward Citations

Loading…